⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

ERAS

Erasca, Inc.

Healthcare · Biotechnology

16.82USD

+1.1200 (+7.13%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
1)

Comparable Revenue

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY————0.00.0
Q1——————
Q2——————
Q3————0.0—
Q4————0.0—
2)

Comparable Earnings Per Share

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY-1.99-.830-.690-.440-.976-.623
Q1-.310-.220-.230-.110-.600—
Q2-.300-.210-.290-.120-.140—
Q3-.290-.200-.110-.110-.130—
Q4-1.11*

Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.

-.198*
-.138*
-.103*
-.132
—